

Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm

On August 28 Asarina Pharma applied to be listed on Nasdaq First North, generating significant interest. On Tuesday, September 4 the company presents to investors at *Aktievällen* in Gothenburg, followed by further events in Stockholm.

"We're developing the world's first dedicated treatment for PMDD, the severest form of PMS," says Peter Nordkild, CEO of Asarina Pharma. "PMDD is a painful condition that impacts 1-in-20 women of a fertile age worldwide—as well as their families, friends and co-workers. I look forward to presenting our clinical data, and the major market potential for investors, in our two largest cities."

PMDD (Premenstrual Dysphoric Disorder) is characterized by severe physical and emotional symptoms in the later part of the menstrual cycle. Current treatments provide only moderate relief of symptoms for most women, and many discontinue treatment to avoid side-effects.

"Sepranolone, the treatment we're developing, has reduced PMDD symptoms by 80 percent in a clinical study," says Nordkild, "and this largely without side effects."

Ongoing Phase IIB study, goal to launch on market early 2020's

A major Phase IIB study is currently underway in Europe, to verify the efficacy and safety of Sepranolone. Following that Asarina Pharma aims to launch the treatment onto the market as soon as 2023. Next year, 2019, the company begins a Phase IIA trial of Sepranolone as a treatment for menstrual migraine, another common, but rarely mentioned, condition that affects 1-in-5 women of a fertile age.

"The conditions are right for us to launch a first-in-class treatment onto a global market," says Nordkild. "Given that effective competing treatments are almost non-existent, I hope that small and large investors alike are drawn to this extraordinary business opportunity, helping women worldwide affected by these disorders remain in control of their lives."

Investor events

[Asarina Pharma](#) will be presented by [Otto Skolling](#), Chief Business Officer at [Aktievällen Göteborg](#), which is organized by Aktiespararna in cooperation with Erik Penser Bank on September 4, 17.00-21.00, at Elite Park Avenue at Kungssportsavenyn 38. Register at [Aktiespararna.se](#). Information about future investment events will be announced later.

For further information, contact Peter Nordkild on +45 25 47 16 46

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com

About Asarina Pharma AB

We are a Swedish biotech company developing Sepranolone: the world's first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years' research into menstrual-related disorders like PMDD, menstrual migraine and menstrual epilepsy. With our new family of GAMSAs compounds (GABA Modulating Steroid Antagonists), we aim to deliver a new generation of safe, targeted treatments for still widely untreated conditions, and to become a leading specialty pharma company in Women's Health.